HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Stephen Safe Selected Research

Estrogen Receptor Modulators (Antiestrogen)

11/2008In vivo profiling of estrogen receptor/specificity protein-dependent transactivation.
5/2008Ligand structure-dependent activation of estrogen receptor alpha/Sp by estrogens and xenoestrogens.
1/2007Differential activation of wild-type estrogen receptor alpha and C-terminal deletion mutants by estrogens, antiestrogens and xenoestrogens in breast cancer cells.
5/2003Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Stephen Safe Research Topics

Disease

158Neoplasms (Cancer)
04/2024 - 03/2002
74Breast Neoplasms (Breast Cancer)
11/2022 - 01/2002
52Pancreatic Neoplasms (Pancreatic Cancer)
01/2024 - 09/2002
41Colonic Neoplasms (Colon Cancer)
03/2023 - 09/2004
19Carcinogenesis
03/2023 - 07/2004
19Neoplasm Metastasis (Metastasis)
11/2022 - 11/2005
13Inflammation (Inflammations)
03/2023 - 01/2011
12Prostatic Neoplasms (Prostate Cancer)
01/2018 - 06/2002
9Parkinson Disease (Parkinson's Disease)
01/2023 - 11/2009
9Lung Neoplasms (Lung Cancer)
06/2022 - 01/2009
9Rhabdomyosarcoma
12/2021 - 02/2013
8Urinary Bladder Neoplasms (Bladder Cancer)
01/2016 - 01/2006
6Endometrial Neoplasms (Endometrial Cancer)
01/2023 - 06/2002
6Leukemia
01/2017 - 12/2005
5Glioblastoma (Glioblastoma Multiforme)
02/2024 - 01/2019
5Liver Neoplasms (Liver Cancer)
01/2022 - 01/2003
4Insulin Resistance
01/2023 - 06/2012
4Skin Neoplasms (Skin Cancer)
10/2016 - 01/2013
3Endometriosis
01/2023 - 01/2020
3Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
12/2021 - 01/2009
3Ovarian Neoplasms (Ovarian Cancer)
01/2021 - 09/2006
3Obesity
01/2019 - 01/2014

Drug/Important Bio-Agent (IBA)

85Proteins (Proteins, Gene)FDA Link
03/2023 - 08/2002
45Sp Transcription FactorsIBA
03/2023 - 03/2007
39LigandsIBA
02/2024 - 06/2002
31Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA
03/2023 - 06/2002
28Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA
01/2023 - 07/2005
26SurvivinIBA
01/2023 - 03/2007
25Estrogens (Estrogen)FDA Link
10/2021 - 06/2002
24Messenger RNA (mRNA)IBA
01/2020 - 08/2002
24Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
11/2016 - 02/2004
23PPAR gammaIBA
06/2010 - 03/2003
21Estrogen Receptor alphaIBA
06/2010 - 01/2002
20Antineoplastic Agents (Antineoplastics)IBA
01/2023 - 03/2002
18Orphan Nuclear ReceptorsIBA
12/2023 - 03/2010
18Estrogen ReceptorsIBA
01/2023 - 06/2002
18Cyclin D1IBA
11/2016 - 03/2003
16Reactive Oxygen Species (Oxygen Radicals)IBA
01/2023 - 08/2010
16Transcription Factors (Transcription Factor)IBA
10/2021 - 05/2003
16Hormones (Hormone)IBA
10/2020 - 06/2002
16Polychlorinated Dibenzodioxins (TCDD)IBA
01/2020 - 06/2002
14indoleIBA
02/2024 - 10/2008
14Cytochrome P-450 CYP1A1 (CYP1A1)IBA
01/2021 - 01/2004
133,3'-diindolylmethane (diindolylmethane)IBA
01/2018 - 04/2006
12tolfenamic acidIBA
02/2014 - 06/2006
10MicroRNAs (MicroRNA)IBA
11/2022 - 02/2006
9PhytochemicalsIBA
04/2024 - 11/2007
9ErbB Receptors (EGF Receptor)IBA
01/2023 - 05/2010
9TriterpenesIBA
10/2021 - 03/2007
9Member 1 Group A Nuclear Receptor Subfamily 4IBA
04/2021 - 09/2010
9methyl 2- cyano- 3,11- dioxo- 18beta- olean- 1,12- dien- 30- oateIBA
01/2020 - 05/2007
91,1- bis(3'- indolyl)- 1- (4- t- butylphenyl)methaneIBA
09/2011 - 09/2004
8LuciferasesIBA
02/2024 - 02/2004
81,1- bis(3'- indolyl)- 1- (4- hydroxyphenyl)methaneIBA
11/2019 - 09/2010
8Proteasome Endopeptidase Complex (Proteasome)IBA
12/2018 - 10/2002
8Betulinic AcidIBA
11/2016 - 03/2007
8rat MIRN27 microRNAIBA
12/2015 - 11/2007
7Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA
02/2014 - 06/2006
7Caveolin 1IBA
05/2010 - 09/2004
6CarcinogensIBA
03/2023 - 03/2004
6Proto-Oncogene Proteins c-metIBA
05/2021 - 07/2009
6Omeprazole (Prilosec)FDA LinkGeneric
07/2020 - 11/2012
6CurcuminIBA
01/2018 - 07/2008
6Glutathione (Reduced Glutathione)IBA
08/2017 - 10/2005
5RNA (Ribonucleic Acid)IBA
01/2019 - 08/2002
5Metformin (Glucophage)FDA LinkGeneric
01/2018 - 12/2013
5AntioxidantsIBA
08/2017 - 05/2008
4QuercetinIBA
05/2023 - 01/2013
4FlavonoidsIBA
01/2023 - 01/2018
4CytokinesIBA
01/2020 - 01/2014
4Phosphotransferases (Kinase)IBA
01/2020 - 12/2005
4Glycyrrhetinic Acid (Po 12)IBA
01/2019 - 05/2007
4Hypoglycemic Agents (Hypoglycemics)IBA
01/2018 - 12/2013
4AcidsIBA
01/2017 - 11/2007
46-methyl-1,3,8-trichlorodibenzofuranIBA
01/2012 - 04/2004
4TamoxifenFDA LinkGeneric
01/2012 - 06/2002
4Estrogen Receptor Modulators (Antiestrogen)IBA
11/2008 - 05/2003
3kaempferolIBA
05/2023 - 12/2021
3ThioredoxinsIBA
01/2023 - 04/2014
3TOR Serine-Threonine KinasesIBA
01/2023 - 10/2014
3Matrix Metalloproteinases (MMPs)IBA
11/2022 - 07/2016
3ResveratrolIBA
06/2022 - 05/2008
3celastrolIBA
10/2021 - 04/2012
3Tryptophan (L-Tryptophan)FDA Link
10/2020 - 10/2015
3Transforming Growth Factors (Transforming Growth Factor)IBA
01/2020 - 05/2016
31,1- bis(3'- indolyl)- 1- (4- chlorophenyl)methaneIBA
01/2020 - 12/2008
3Leflunomide (Arava)FDA LinkGeneric
05/2018 - 11/2012
3Flutamide (Eulexin)FDA LinkGeneric
05/2018 - 07/2014
3Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
01/2018 - 01/2011
31- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA
01/2018 - 02/2015
3indole-3-carbinolIBA
02/2017 - 10/2008
3tranilastIBA
02/2017 - 07/2014
3bardoxolone methylIBA
01/2017 - 07/2005
3Hydroxyl RadicalIBA
01/2017 - 03/2004
3NF-kappa B (NF-kB)IBA
11/2016 - 08/2002
3Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
05/2016 - 07/2005

Therapy/Procedure

22Drug Therapy (Chemotherapy)
06/2022 - 11/2005
12Therapeutics
01/2023 - 06/2002
6Chemoprevention
12/2020 - 06/2012
4Aftercare (After-Treatment)
01/2018 - 10/2002